ZIMAR MIRPINE VALTA ZEMER MIRTZ MIRTZ MIPINE ELAXINE ELAXINE CHARMFIL MIRTAZEP MIRTAZEP NOTENSE NOTENSE TIZIDAN TIZIDAN REMERON MEMRON TNSLES TNSLES MIRTON MIRTON TIZAPINE TIZAPINE RAMARGON RAMARGON

Dose: 15 to 45 mg/day
Single Dose: 30 (30)
Frequency: As recommended.
Route: PO
Instructions:

. It is of Synthetic origin and belongs to Piperazinoazepine. . The Molecular Weight of Mirtazapine is 265.40.

Mirtazapine

The severe or irreversible adverse effects of Mirtazapine, which give rise to further complications include Jaundice, Jaundice, Increase in liver enzymes.The signs and symptoms that are produced after the acute overdosage of Mirtazapine include Convulsions, Leucopenia, Postural hypotension, Tremor, Mania, Granulocytopenia, Reversible agranulocytosis.The symptomatic adverse reactions produced by Mirtazapine are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Headache, Drowsiness, Skin rashes, Sedation, Increased weight, Nightmares, Increased appetite, Agitation, Skin rashes, dizziness.

Mirtazapine is primarily indicated in conditions like Depression, Depressive illness.

Mirtazapine is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementAlcoholDiazepamPhenelzineVORICONAZOLEVoriconazole may increase the serum concentration of mirtazapine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects Vortioxetineincreases the level of vortioxetineuse alternative These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Elevation in ALT or AST

Drug should not be given to Paediatrics, and Pregnant Mothers.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

All patients being treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases. Should be given cuation with hepatic impairment .